[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  Ozmosi [@OzmosiHealth](/creator/twitter/OzmosiHealth) on x 2633 followers Created: 2025-07-21 11:32:28 UTC $GLUE Phase X study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for treating inflammatory diseases, begins with dosing of first subjects by Monte Rosa Therapeutics. More Info: $XBI $IBB $XPH $PPH  XXX engagements  **Related Topics** [$pph](/topic/$pph) [$xph](/topic/$xph) [$ibb](/topic/$ibb) [$xbi](/topic/$xbi) [more info](/topic/more-info) [monte](/topic/monte) [$glue](/topic/$glue) [Post Link](https://x.com/OzmosiHealth/status/1947258369326334140)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Ozmosi @OzmosiHealth on x 2633 followers
Created: 2025-07-21 11:32:28 UTC
$GLUE Phase X study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for treating inflammatory diseases, begins with dosing of first subjects by Monte Rosa Therapeutics.
More Info: $XBI $IBB $XPH $PPH
XXX engagements
/post/tweet::1947258369326334140